Crispr Stem & Therapeutics (CST) is developing a patented cardio-protective CRISPR-based stem cell protocol to restrict the damage to the heart following acute heart attack and chronic heart failure. The company's technology will use CRISPR to genetically modify the patient's own stem cells, which are then treated by Crispr Stem & Therapeutics protocol and implanted in the patient with acute ischemic heart disease. The company's protocol was tested in several proof-of-concept experiments both in vitro and in vivo in animal models and showed dramatically decreased damage to the heart. The protocol aims to increase patients' life expectancy and quality of life, enable quick recovery, shorten hospitalization, and eliminate the risk of rejection. The company received recognition from the Israeli Innovation Authority (Tnufa funding) and European Commission with two Seals of Excellence.